Do we need B7-H3 immunohistochemistry for the inclusion of children with high-grade central nervous system tumors in clinical trials targeting B7-H3?
Our study of B7-H3-expression in the largest pHG-CNS tumor set to date revealed significant interpatient variability and numerous negative cases. Our results urge for tumor tissue acquisition at enrollment in B7-H3 targeting therapeutic trials (including CAR-T cells) in order to thoroughly assess the value of IHC B7-H3 expression as biomarker and, ultimately, to allow for more tailored therapy.
Authors
- Raoull Hoogendijk (ORCID: https://orcid.org/0000-0002-8033-2093)
- Esther van Mastrigt (ORCID: https://orcid.org/0000-0002-2528-3030)
- Bastiaan B.J. Tops (ORCID: https://orcid.org/0000-0002-1699-8210)
- Dannis G. van Vuurden (ORCID: https://orcid.org/0000-0002-1364-9007)
- Mariëtte E.G. Kranendonk (ORCID: https://orcid.org/0000-0001-9683-7494)
- Eelco W. Hoving (ORCID: https://orcid.org/0000-0002-5587-0439)
- Pieter Wesseling (ORCID: https://orcid.org/0000-0001-5453-5201)
- Sabine Plasschaert (ORCID: https://orcid.org/0000-0003-3391-3618)
- Thijs J M van den Broek (ORCID: https://orcid.org/0000-0003-3034-6160)
- Lennart A. Kester (ORCID: https://orcid.org/0000-0002-8259-9971)
- Jasper van der Lugt (ORCID: https://orcid.org/0000-0002-8186-338X)
- Julie A S Lammers
- Nelleke Tolboom (ORCID: https://orcid.org/0000-0002-8005-2833)
- Ella de Boed
Institutions
- Utrecht University (NL)
- University Medical Center Utrecht (NL)
- Princess Máxima Center (NL)
- Erasmus MC Cancer Institute (NL)
- Amsterdam University Medical Centers (NL)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1093/neuonc/noaf095
- Citations
- 4
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 6.50